Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Melanoma, Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT04866680
What this trial is testing

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

Who this might be right for
Melanoma
Institut de Cancérologie de Lorraine 136
Large-scale testing (Phase 3)UnknownNCT00000124
What this trial is testing

Collaborative Ocular Melanoma Study (COMS)

Who this might be right for
Choroid NeoplasmsUveitis
National Eye Institute (NEI)
Testing effectiveness (Phase 2)Study completedNCT01256359
What this trial is testing

Docetaxel With or Without AZD6244 in Melanoma

Who this might be right for
Melanoma
University of Oxford 83
Testing effectiveness (Phase 2)Looking for participantsNCT07230613
What this trial is testing

Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

Who this might be right for
Cutaneous Melanoma, Stage IIIMucosal Melanoma
UNICANCER 50
Early research (Phase 1)Study completedNCT04291079
What this trial is testing

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Who this might be right for
Cancer
Scholar Rock, Inc. 112
Not applicableUnknownNCT05744076
What this trial is testing

Analysis of Circulating Exosomes in Melanoma Patients

Who this might be right for
Melanoma
Centre Hospitalier Universitaire de Besancon 150
Early research (Phase 1)Looking for participantsNCT07600476
What this trial is testing

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Who this might be right for
Cutaneous MelanomaMucosal MelanomaCutaneous Squamous Cell Carcinoma (CSCC)+2 more
Kupando GmbH 21
Early research (Phase 1)Study completedNCT03021460
What this trial is testing

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Who this might be right for
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7+4 more
Mayo Clinic 20
Testing effectiveness (Phase 2)Ended earlyNCT01433991
What this trial is testing

E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Who this might be right for
Advanced Solid Tumors
Eisai Inc. 30
Large-scale testing (Phase 3)Study completedNCT03430297
What this trial is testing

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Who this might be right for
Metastatic MelanomaUnresectable Melanoma
Shanghai Junshi Bioscience Co., Ltd. 256
Not applicableStudy completedNCT01444560
What this trial is testing

MiRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Who this might be right for
Cutaneous MelanomaNevi
Ruhr University of Bochum 21
Not applicableStudy completedNCT04035447
What this trial is testing

Symptom Management for YA Cancer Survivors

Who this might be right for
CancerYoung AdultPain+7 more
Duke University 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Not applicableEnded earlyNCT02355574
What this trial is testing

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

Who this might be right for
Cutaneous Melanoma
Castle Biosciences Incorporated 301
Early research (Phase 1)Looking for participantsNCT05859074
What this trial is testing

MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Who this might be right for
Cutaneous Squamous Cell CarcinomaSCC - Squamous Cell CarcinomaBasal Cell Carcinoma+16 more
Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)Ended earlyNCT03300843
What this trial is testing

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Who this might be right for
MelanomaGastrointestinal CancerBreast Cancer+2 more
National Cancer Institute (NCI) 1
Early research (Phase 1)Study completedNCT01621490
What this trial is testing

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Who this might be right for
Advanced MelanomaMetastatic Melanoma
Bristol-Myers Squibb 170
Not applicableLooking for participantsNCT07555210
What this trial is testing

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))Renal Cell Carcinoma (Kidney Cancer)Melanoma (Skin Cancer)+5 more
Jessica Mezzanotte Sharpe 25
Early research (Phase 1)Ended earlyNCT04116320
What this trial is testing

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Who this might be right for
MelanomaBreast CancerMerkel Cell Carcinoma+10 more
Craig L Slingluff, Jr 5
Early research (Phase 1)Study completedNCT01652547
What this trial is testing

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Who this might be right for
Metastatic Melanoma and Merkel Cell Carcinoma
Novartis Pharmaceuticals 10
Next Page